## Medi-Cal Rx Weekly Wrap-Up for April 29 – May 5

## May 6, 2022

Stay up to date with all that's happening at Medi-Cal Rx by visiting the <u>Bulletins & News</u> page and signing up for the <u>Medi-Cal Rx Subscription Service</u> to receive notification of future alerts.

Here are the latest alerts:

## April 29, 2022

- <u>Electronic Claims Agreement Submission Deadline Extended to July 31, 2022</u>: All
  participating Medi-Cal Rx pharmacy providers and billers will need to submit a *Medi-Cal Rx Telecommunications Provider and Biller Application/Agreement Form* (DHCS 6500) to
  continue submitting electronic claims without interruption, and the completed
  Application/Agreement must be <u>received</u> by July 31, 2022.
- <u>Update: Drug Utilization Review Claim Edits Will Not be Reinstated on May 1, 2022</u>: Drug Utilization Review (DUR) edits originally proposed to be reinstated May 1, 2022, will not take place. Additional mitigations (i.e., claim edits and prior authorization [PA] requirement suspensions), as well as the transition policy, will remain in effect until further notice.

## May 5, 2022

- Medi-Cal Rx Operational Updates: Claim edits originally proposed to be reinstated May 1, 2022, will not occur. Medi-Cal Rx will continue to utilize historical prior authorization and claim data for the transition policy beyond July 1, 2022, and Medi-Cal Rx has created a Special Populations Clinical Liaison team to serve the needs of populations enrolled in California Children's Services, the Genetically Handicapped Persons Program, and those who have specialty behavioral health conditions.
- <u>Diabetic Supplies Therapeutic Continuous Glucose Monitoring (CGM) Systems</u>: The List of Covered Therapeutic Continuous Glucose Monitoring (CGM) Systems has been updated to reflect product-specific restriction changes for Abbott Diabetes Care Sales Corporation's FreeStyle Libre Sensor Kit and FreeStyle Libre 2 Sensor Kit.